← All trials
NCT05859464
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2023
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2025
- First posted
- May 16, 2023
- Last posted
- Nov 30, 2023
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zai Lab Pty. Ltd.Lead sponsor
- MerckCollaborator
- Zai Lab Pty. Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.